Premium
The use of upper extremity anthropometrics in the clinical assessment of patients with amyotrophic lateral sclerosis
Author(s) -
Kasarskis Edward J.,
Berryman Susan,
English Tony,
Nyland John,
Vanderleest Jennifer G.,
Schneider Andrew,
Berger Rolando,
McClain Craig
Publication year - 1997
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/(sici)1097-4598(199703)20:3<330::aid-mus10>3.0.co;2-4
Subject(s) - amyotrophic lateral sclerosis , medicine , ciliary neurotrophic factor , anthropometry , muscle atrophy , atrophy , clinical trial , vital capacity , physical medicine and rehabilitation , physical therapy , surgery , neurotrophic factors , lung , disease , lung function , receptor , diffusing capacity
We evaluated the feasibility of using upper extremity anthropometrics to monitor the clinical status of 18 patients with amyotrophic lateral sclerosis (ALS). The bone‐free arm muscle area (AMA) was computed using measurement of triceps skinfold thickness and the mid‐upper arm circumference according to published formulae. The AMA correlated significantly with body mass, isokinetic muscle force generation, cross‐sectional muscle area on computerized tomography scanning, and pulmonary functions including forced vital capacity and maximal voluntary ventilation. Serial determinations of AMA demonstrated a decline in 10 of 13 patients over 6 months. We pilot tested the use of AMA in a clinical trial of ciliary neurotrophic factor (CNTF) in the treatment of ALS. The AMA progressively decreased by 13%, 15%, and 30% in ALS patients treated with 0 μg CNTF/kg, 15 μg CNTF/kg, and 30/μg CNTF/kg, respectively, over a 9‐month treatment period. We conclude that measurement of AMA provides a simple, inexpensive method to monitor the progression of muscle atrophy in ALS patients. The technique does not require effort on the part of the patient and as such, appears to have potential utility as an outcome measure in clinical drug trials. © 1997 John Wiley & Sons, Inc. Muscle Nerve , 20, 330–335, 1997